Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL34250 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL13287212 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1815791 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157427 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1319766 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL29424282 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157381 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL11215595 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL16241872 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL3136078 | 0.94 | GFER (0.91) | DRD1DRD2KDM4ERECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2842 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4460293-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-116966129-A | Stable topical fenoldopam compositions | 塔罗制药工业有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20230330098-A1 | USE OF FENOLDOPAM FOR THE TREATMENT OF HEMOLYTIC UREMIC SYNDROME | FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO (IT) | 2023-10-19 | — | — | US | claimed |
| WO-2023168053-A2 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2023-09-07 | — | — | WO | claimed |
| US-6699497-B1 | PERMEATION ENHANCER | ALZA CORPORATION | 2004-03-02 | — | — | US | claimed |
| EP-1324805-A1 | METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE | Medtronic, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2002096422-A2 | COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2002026318-A1 | METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE | MEDTRONIC, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| EP-1100476-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000004886-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0087319-A1 | R- and S-isomers of 6-chloro-7,8-dihydroxy-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | claimed |